Klinische Wochenschrift

, Volume 60, Issue 5, pp 257–261 | Cite as

Nebenwirkungen der Polychemotherapie bei metastasierten Hodentumoren

  • J. H. Hartlapp
  • N. Jaeger
  • P. Fischer
  • L. Weißbach
Originalien

Zusammenfassung

25 Patienten mit metastasierten, nicht-seminomatösen Hodentumoren wurden operiert und zytostatisch mit einer Kombination aus Velbe, Bleomycin, Cis-Platin und/oder Ifosfamid behandelt. In 22 Fällen konnte eine anhaltende Vollremission bei einer mittleren Beobachtungszeit von 23 Monaten erreicht werden. 2 Patienten verstarben durch einen rasch auftretenden Tumorprogreß an postoperativen Komplikationen nach Second-look-LA. Ein Patient erlag nach Chemotherapie einem septischen Schock.

Die Morbidität dieser effektiven Chemotherapie darf nicht unterschätzt werden. Passagere Panmyelophtise, Anorexie, Alopezie und Hyperpigmentationen sind unvermeidbar. Schweres Erbrechen, Elektrolytentgleisung, hämorrhagische Cystitis, Anämie, Septikämien lassen sich durch supportive Maßnahmen reduzieren. Auftretende Septikämien sind durch eine geeignete Antibiotika-Kombination ohne zusätzlichen Tubulusschaden zu beherrschen. Schwerwiegende Dauerschäden insbesondere an Innenohr und Niere können vermieden werden.

Schlüsselwörter

Hodentumoren Polychemotherapie Nebenwirkungen supportive Maßnahmen 

Side-effects of polychemotherapy in metastatic testicular neoplasms

Summary

25 Patients with metastatic non-seminomatous testicular neoplasms were treated by surgery and cytostatic therapy using a combination consisting of Velban, Bleomycin, Cis-Platinum and/or Ifosfamid. In 22 patients this procedure induced a persistant complete remission with a mean observation time of 23 months. 2 patients died because of post-surgical complications after a second-look-lymphadenectomy. They suffered from rapidly progressive tumor disease. One patient died in a septicemia during chemotherapy.

Our experience is that morbidity of an effective chemotherapy should not be underestimated. Transient bone marrow suppression, anorexia, alopecia and hyperpigmentation are unavoidable. However, severe vomiting, disturbed electrolyte metabolism, hemorrhagic cystitis, anemia and septicemia can well be managed by respective supportive care. Septicemia, for instance, may be treated with appropriate antibiotics without inducing tubular necrosis. Supportive measures also will avoid severe chronic defects of ear and kidney function.

Key words

Adverse effects Drug therapy Testicular neoplasms Critical care 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Cheng E, Cvitkovic E, Wittes R (1978) Germ cell tumors (II): VAB II in metastatic testicular cancer. Cancer 42:2162–2168Google Scholar
  2. 2.
    Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH (1978) Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41:1274–1281Google Scholar
  3. 3.
    Einhorn LH, Donohue JB (1977) Cis-diammine-dichloro-platinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293–298Google Scholar
  4. 4.
    Einhorn LH, Donohue JP (1979) Combination chemotherapy in disseminated testicular cancer: The Indiana University experience. Seminars in Oncology, Vol 6, No 1, pp 87–93Google Scholar
  5. 5.
    Fillastre JP, Laumonier R, Humpert G, Dubois D, Metayer J, Delpect A, Leroy J, Robert M (1973) Acute renal failure associated with combined gentamicin and cephalothin therapy. Br Med J 2:396–397Google Scholar
  6. 6.
    Gropp C, Schmidt M, Havemann K (1979) Was ist gesichert in der Therapie maligner Hodentumoren? Internist 20:607–612Google Scholar
  7. 7.
    Hartlapp JH, Drebber G, Noack D, Walbert G, Illiger HJ, Labedzki L (1979) Parenteral nutrition during aggressive chemotherapy accelerates neutrophilic granulopoetic recovery. Proc Int Soc Haematol IV, 51Google Scholar
  8. 8.
    Hill IM, Loeb E, MacLellan A (1975) Clinical studies of platinum coordination compounds in the treatment of various malignant diseases: Cancer Chemother Rep 59:647–659Google Scholar
  9. 9.
    Krakoff JH (1979) Nephrotoxicity of cis-dichlorodiammineplatinum (II). Cancer Treat Rep Vol 63, No 9–10, pp 1523–1525Google Scholar
  10. 10.
    Li MC, Whitmore WF, Golby RB (1960) Effects of combined drug therapy on metastatic cancer of the testis. J Am Med Assoc 174:1291–1299Google Scholar
  11. 11.
    Merrin C, Takita H, Weber R, Wajsmann L, Baumgartner G, Murphy GP (1976) Combination radical surgery and multiple sequential chemotherapy for the treatment of advanced carcinoma of the testis (Stage III). Cancer 37:20–29Google Scholar
  12. 12.
    Monfardini S, Bajetta E, Musumeci R, Bonadonna G (1972) Clinical use of adriamycin in advanced testicular cancer. J Urol 108:293–296Google Scholar
  13. 13.
    Peckham MJ, McElwain TJ, Hendry WF (1979) Combined management of malignant teratoma of the testis. Lancet II:267–270Google Scholar
  14. 14.
    Samuels ML, Johnson DE, Holoye PY (1972) Continuous intravenous bleomycin therapy with vinblastine in state III testicular neoplasia. Cancer Chemother Rep 59:563–570Google Scholar
  15. 15.
    Samuels ML, Holoye PY, Johnson DE (1975) Bleomycin combination and chemotherapy in the mangement of testicular neoplasia. Cancer 36:318–326Google Scholar
  16. 16.
    Schilsky RL, Anderson T (1979) Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90:929–931Google Scholar
  17. 17.
    Schmidt CG (1980) Stellung der Chemotherapie in der Behandlung der teratoiden und embryonalen Hodentumoren. Urologe B 20:119–128Google Scholar
  18. 18.
    Schmoll HJ, Rhomberg W, Diehl V (1978) Ifosfamide (NSC-109724): Activity in testicular cancer using mono- and combination therapy. Curr Chemother 1089–1191Google Scholar
  19. 19.
    Seeber S, Scheulen ME, Osieka R (1978) Development of chemotherpay programs containing vinblastine, bleomycin, adriamycin and cis-dichlorodiamminoplatinum (II). In: Carter SK, Crooke ST, Umezawa H, Bleomycin (eds) Current status and new developments. Academic Press, New York San Francisco London, pp 215–226Google Scholar
  20. 20.
    Serrou B, Cupissol D, Favier L (1980) Phase I and II study of peripheral intravenous nutrition (PIVN) in patients bearing solid tumors. A simple and valuable adjunct to chemotherapy. Abstract of the 5th Annual Meeting of the Medical Oncology Society. Springer, Berlin Heidelberg New York, p 45Google Scholar
  21. 21.
    Spigel SC, Coltman CA jr (1974) Vinblastine and bleomycin therapy for disseminated testicular tumors. Cancer Chemother Rep 58:213–216Google Scholar
  22. 22.
    Weißbach L, Eckstein P, Vahlensieck W, Scheef W (1977) Clinical experience with holoxan in malignant testicular tumors. Proc Intern Holoxan-Symp. ASTA-Werke AG, Bielfeld, S 118–121Google Scholar
  23. 23.
    Weißbach L, Jaeger N, Hartlapp JH (1980) Second-Look-Operation in der Urologie unter besonderer Berücksichtigung der Hodentumoren. Muench Med Wschr 122 Nr 18, 659–663Google Scholar
  24. 24.
    Hartlapp JH, Weißbach L (1981) Zur Notwendigkeit der Unterteilung des Stadium II bei Hodentumoren. Karger, Basel (im Druck)Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • J. H. Hartlapp
    • 1
  • N. Jaeger
    • 2
  • P. Fischer
    • 3
  • L. Weißbach
    • 2
  1. 1.Medizinische Universitätsklinik Bonn-VenusbergGermany
  2. 2.Urologische Universitätsklinik Bonn-VenusbergGermany
  3. 3.Radiologische Universitätsklinik Bonn-VenusbergGermany

Personalised recommendations